Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy
Primary Purpose
Nicotine Addiction
Status
Recruiting
Phase
Phase 3
Locations
Mongolia
Study Type
Interventional
Intervention
Cytisine
Nicotine Replacement Therapy (NRT)
Sponsored by
About this trial
This is an interventional treatment trial for Nicotine Addiction focused on measuring Smoking Cessation, Nicotine Replacement Therapy, Cytisine
Eligibility Criteria
Inclusion Criteria:
- Seeking smoking cessation treatment
- Ages 18 years or older
- Currently smoking > 5 cigarettes per day
- Willingness to make quit attempt with pharmacotherapy
- Able to provide verbal and written informed consent
- Have telephone access
Exclusion Criteria:
- Pregnancy or currently breastfeeding
- Current users of NRT (patch, gum, lozenge)
- Current users of non_NRT smoking cessation pharmacotherapy
- Enrolled in another smoking cessation program (non-governmental)
- Clinical disorder that contraindicates use of NRT or Cytisine (heart attack, stroke, severe angina within the past 2 weeks, uncontrolled hypertension, phaeochromocytoma, severe mental illness)
Sites / Locations
- Mongolian National University of Medical SciencesRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Usual Care Group
Treatment Group
Arm Description
Subjects are asked to completely stop smoking on their quit day and use a daily Nicotine Replacement Therapy (NRT) patch for 25 days.
Subjects will start a 25-day course of Cytisine tablets started during the four days before the quit date and are asked to reduce smoking during this time.
Outcomes
Primary Outcome Measures
Length of abstinence after 25 day course of Cytisine.
Continuous abstinence is defined as <5 cigarettes smoked since quit date. Subjects will complete survey to determine number of cigarettes smoked since quit day.
Secondary Outcome Measures
Length of abstinence after 25 days of NRT
Continuous abstinence is defined as <5 cigarettes smoked since quit date. Subjects will complete survey to determine number of cigarettes smoked since quit day.
Full Information
NCT ID
NCT04126135
First Posted
October 11, 2019
Last Updated
August 7, 2023
Sponsor
Loma Linda University
Collaborators
Pfizer, Mongolian National University of Medical Sciences
1. Study Identification
Unique Protocol Identification Number
NCT04126135
Brief Title
Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy
Official Title
Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy (NRT) in the National Smoking Cessation Program of Mongolia: A Pragmatic Non-Inferiority Trial
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 27, 2022 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Loma Linda University
Collaborators
Pfizer, Mongolian National University of Medical Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A pragmatic, single blinded, randomized, controlled non-inferiority trial of Cytisine versus Nicotine Replacement Therapy for continuous abstinence is conducted in the government run primary health hospitals in Mongolia.
Detailed Description
Rationale: In Mongolia, smoking cessation assistance in the governmental health sector consists of behavioral counseling and a 3-week regimen of the NRT patch that costs 175 USD. This cost for low income adults limits effectiveness. A 2014 study documented the superiority and lower cost (<20 USD) of Cytisine versus NRT for continuous abstinence. Trial investigators are testing the comparative effectiveness of Cytisine in the "real life setting" of their national health care system and, if proven effective, will include coverage for Cytisine in the national health plan.
Research Question/Objective: To determine whether a 25 day course of Cytisine tablets is at least as effective as 25 days of NRT in helping smokers remain abstinent for at least one month.
Design: A pragmatic, single blinded, randomized, controlled non-inferiority trial.
Setting: Nine governmental primary care centers in Ulaanbaatar, Mongolia, and outskirts.
Participants: Mongolian adult smokers referred to government-run addiction units.
Intervention and procedures: Participants are randomized to 5 weeks of treatment (n=352) or usual care (n=352) and a 6-month follow-up. The treatment consists of a 25-day course of Cytisine tablets and behavioral counseling. Usual care consists of 25 days of NRT and behavioral counseling.
Measurements: The primary outcome is continuous abstinence (< 5 cigarettes smoked since quit date) at 1 month. Secondary outcomes include 7-day point prevalence abstinence rates and adverse events.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Nicotine Addiction
Keywords
Smoking Cessation, Nicotine Replacement Therapy, Cytisine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
700 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Usual Care Group
Arm Type
Active Comparator
Arm Description
Subjects are asked to completely stop smoking on their quit day and use a daily Nicotine Replacement Therapy (NRT) patch for 25 days.
Arm Title
Treatment Group
Arm Type
Experimental
Arm Description
Subjects will start a 25-day course of Cytisine tablets started during the four days before the quit date and are asked to reduce smoking during this time.
Intervention Type
Drug
Intervention Name(s)
Cytisine
Intervention Description
Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.
Intervention Type
Drug
Intervention Name(s)
Nicotine Replacement Therapy (NRT)
Intervention Description
Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
Primary Outcome Measure Information:
Title
Length of abstinence after 25 day course of Cytisine.
Description
Continuous abstinence is defined as <5 cigarettes smoked since quit date. Subjects will complete survey to determine number of cigarettes smoked since quit day.
Time Frame
One month after quit date
Secondary Outcome Measure Information:
Title
Length of abstinence after 25 days of NRT
Description
Continuous abstinence is defined as <5 cigarettes smoked since quit date. Subjects will complete survey to determine number of cigarettes smoked since quit day.
Time Frame
One month after quit date
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Seeking smoking cessation treatment
Ages 18 years or older
Currently smoking > 5 cigarettes per day
Willingness to make quit attempt with pharmacotherapy
Able to provide verbal and written informed consent
Have telephone access
Exclusion Criteria:
Pregnancy or currently breastfeeding
Current users of NRT (patch, gum, lozenge)
Current users of non_NRT smoking cessation pharmacotherapy
Enrolled in another smoking cessation program (non-governmental)
Clinical disorder that contraindicates use of NRT or Cytisine (heart attack, stroke, severe angina within the past 2 weeks, uncontrolled hypertension, phaeochromocytoma, severe mental illness)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pramil N Singh, DrPH
Phone
(909) 651-5732
Email
psingh@llu.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Anne Berit Petersen, PhD
Phone
(909) 558-1000
Ext
42846
Email
abpetersen@llu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pramil N Singh, DrPH
Organizational Affiliation
Loma Linda University Health
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Davaalkham Dambadarjaa, MD
Organizational Affiliation
Mongolian National University of Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mongolian National University of Medical Sciences
City
Ulaanbaatar
Country
Mongolia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Davaalkham Dambardajaa, MD
Phone
976-11328640
Email
davaalkham@mnums.edu.mn
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy
We'll reach out to this number within 24 hrs